Connect with us

Technology

Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting

Published

on

Validation data presented at the 2025 Alzheimer’s & Parkinson’s Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer’s pTau217 pathology than the benchmark Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) 

BELFAST, Northern Ireland, April 4, 2025 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® Platform validation data for two novel assessments of cognitive impairment in Alzheimer’s dementia (AD), and proof-of-concept data in amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) at the AD/PD™ 2025 in Vienna, Austria.

“We are excited to share data validating NeuLogiq Platform cognitive tasks to measure memory, executive function and psychomotor function in broader neurodegenerative indications. We also demonstrated sensitivity to underlying Alzheimer’s pathology, correlating to plasma ptau217 status,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “Additionally, our CNS-101 study demonstrated that patients could achieve high levels of adherence performing repeated cognitive and EEG tests at home to capture high quality data, making them suitable for use in clinical trials where precise measurement at the individual level is critical. Separately, data presented from our CNS-102 study provides proof-of-concept that NeuLogiq can capture data relevant in ALS-FTD, including patients with profound motor impairments. Collectively, these data confirm that the NeuLogiq Platform has the potential to enable earlier detection of disease and provide biopharma with longitudinal real-world data that can streamline clinical studies.” 

The first poster, titled “Neuropsychological phenotyping of Alzheimer’s dementia at home, using the Cumulus NeuLogiq Platform with plasma biomarkers,” featured data demonstrating that patients are willing and able to perform repeated cognitive and EEG testing at home, and the NeuLogiq Platform endpoints show greater separation with AD pathology (pTau217) than the benchmark endpoint (ADAS-Cog) throughout the study. Importantly, these endpoints accord with standard benchmarks and demonstrate patterns of patient impairment consistent with the literature. EEG biomarkers, including passive and task-based measures, demonstrate morphology and group differences as expected based on the literature.

The second poster titled, “Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations,” provided initial evidence that the NeuLogiq Platform can capture speech fluency and emotion recognition decline in patients living with ALS, offering potential utility as a digital biomarker of cognitive decline, in addition to providing proof-of-concept that the platform can capture meaningful neuropsychological data, relevant to the heterogeneity of the ALS-FTD phenotype.

Cumulus continues to advance the NeuLogiq Platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit www.cumulusneuro.com

About Alzheimer’s Disease and pTau217
Alzheimer’s is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, mood swings, changes in behavior and personality, and difficulty with language and communication. Currently, there is no known cure for Alzheimer’s. Today, earlier diagnosis can enable patients to make lifestyle changes, including exercising and decreasing alcohol consumption, both of which have been shown to slow disease progression. In the future, having the ability to diagnose patients earlier may expedite enrollment in clinical studies and the identification of new treatments. 

pTau217, a phosphorylated fragment of the tau protein, is a promising blood-based biomarker for detecting Alzheimer’s disease (AD) pathology, showing high accuracy in identifying amyloid and tau pathology, and potentially distinguishing AD from other neurodegenerative disorders.

About Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) 
ALS and FTD are two neurodegenerative diseases that share some similarities but also have distinct characteristics. ALS, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of motor neuron function and eventually causing muscle weakness and paralysis. FTD involves the progressive degeneration of neurons in the areas of the brain behind the forehead (the frontal lobe) and behind the ears (the temporal lobes), leading to changes in personality, behavior, and language. 

About Cumulus Neuroscience 
Our mission is to generate the data and insights required to accelerate the diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world. At Cumulus Neuroscience, we are advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform designed with 10 of the world’s leading pharma companies. This novel platform provides the critical data and insights needed for faster, more robust and cost-effective decision-making in clinical trials and patient care. NeuLogiq enables study sponsors to capture large amounts of real-world clinical data repeatedly over time, across multiple behavioral and physiological domains, in the clinic and at home. Together with machine learning (ML) analytics, Cumulus simplifies and improves the robustness of CNS clinical trials, providing objective assessment of study inclusion and treatment outcomes.

FOR MORE INFORMATION
Tina Sampath
tina.sampath@cumulusneuro.com 
Tel: 415.694.1175

Logo: https://mma.prnewswire.com/media/2657658/Cumulus_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cumulus-neuroscience-presents-data-at-adpd-2025-annual-meeting-302420326.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

SiriusXM Declares Quarterly Cash Dividend

Published

on

By

NEW YORK, July 22, 2026 /PRNewswire/ — SiriusXM (NASDAQ: SIRI) today announced that its Board of Directors declared a quarterly cash dividend of $0.27 per share of common stock. This regular quarterly dividend is payable in cash on August 26, 2026, to stockholders of record at the close of business on August 10, 2026.

About Sirius XM Holdings Inc.
SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; an expansive podcast network; and a suite of business and advertising solutions. Together, SiriusXM reaches a combined monthly audience of approximately 255 million listeners. SiriusXM offers a broad range of content for listeners everywhere they tune in with a diverse mix of live, on-demand, and curated programming across music, talk, news, and sports. For more about SiriusXM, please go to: www.siriusxm.com.

Source: SiriusXM

Investor contacts:
Jennifer DiGrazia
investor.relations@siriusxm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/siriusxm-declares-quarterly-cash-dividend-302832548.html

SOURCE Sirius XM Holdings Inc.

Continue Reading

Technology

Shutterstock Announces Capital Allocation Update

Published

on

By

NEW YORK, July 22, 2026 /PRNewswire/ — Shutterstock, Inc. (NYSE: SSTK) (the “Company”), a family of brands delivering scalable creative and GenAI solutions to help customers fuel great work, today announced that at a meeting held on July 20, 2026 its Board of Directors (the “Board”) resolved to suspend the Company’s future quarterly cash dividend.

The Board’s determination reflects its ongoing review of the Company’s capital-allocation priorities and its focus on deploying capital to support long-term value creation for shareholders, including reducing debt, minimizing related interest expense and strengthening financial flexibility.

The Board will continue to evaluate the Company’s capital allocation priorities as part of its regular governance process. Any future declaration and payment of dividends, and the amount thereof, will remain subject to the discretion of the Board and will depend upon the Company’s results of operations, financial condition, capital requirements, contractual restrictions, applicable law, and such other factors as the Board deems relevant.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements may discuss intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise. Forward-looking statements speak only as of the date they are made and should not be relied upon as predictions of future events, as there can be no assurance that the events or circumstances reflected in these statements will occur. Forward-looking statements can often, but not always, be identified by the use of forward-looking terminology including “believes,” “could,” “expects,” “intends,” “may,” “might,” “ongoing,” “plans,” “seeks,” “should,” “will,”  or the negative of these words and phrases, other variations of these words and phrases or comparable terminology, but not all forward-looking statements include such identifying words. Forward-looking statements are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those indicated or anticipated by such forward-looking statements. The forward-looking statements in this press release relate to, among other things, the Company’s capital allocation strategy, the suspension of the Company’s quarterly cash dividend, the Company’s plans with respect to debt reduction, interest expense management and financial flexibility, and any future declaration and payment of dividends. For a discussion of factors that could cause actual results to differ materially from those contemplated by forward-looking statements, see the sections captioned “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company’s Quarterly Reports on Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission. While those factors are considered representative, no list of risk factors should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. The Company assumes no obligation to update forward-looking statements, and the Company disclaims any such obligation, except as may be required by law.

About Shutterstock
Shutterstock is in the business of turning ideas into impact. Powered by a global network of millions of creators and our cutting-edge technology, we provide businesses, creatives, and brand leaders with the essential, universal ingredients to make their work more effective. Shutterstock offers access to one of the world’s largest and most diverse collections of high-quality licensable assets, specialized training datasets, evaluation tools, and end-to-end strategic partnerships for the full model training lifecycle, as well as advertising and distribution solutions, exclusive editorial content, and full-service studio production—delivering unparalleled resources to fuel great work.

Discover our impact at www.shutterstock.com and connect with us on LinkedIn, Instagram, X, Facebook and YouTube.

View original content to download multimedia:https://www.prnewswire.com/news-releases/shutterstock-announces-capital-allocation-update-302832484.html

SOURCE Shutterstock, Inc.

Continue Reading

Technology

ICI Welcomes Bipartisan Sponsors of Bill to Stop States from Seizing Long-Term Investors’ Savings

Published

on

By

WASHINGTON, July 22, 2026 /PRNewswire/ — The Investment Company Institute released the following Viewpoints blog. To learn more about why this issue matters and how the SAFER Act would help protect American investors, watch our video on LinkedIn.

Millions of American investors have adopted the advice given by financial advisors to invest for the long term and then leave those savings alone. In some states, however, following this guidance can get your account seized. That was the warning sounded at an event featuring the sponsors of the bipartisan SAFER Act, Representatives Sam Liccardo (D-CA) and Mike Lawler (R-NY), who joined ICI leaders to make the case for a federal solution to the problem of state unclaimed property laws that can treat buy-and-hold investors as though they have disappeared. 

ICI President and CEO Eric Pan opened the event by outlining the nature of this growing threat. More than 128 million Americans invest in regulated funds, many with the intention of holding them for years, following the advice of many financial educators to “stay in the market, invest for the long term.” They put their money away and go about their lives, confident that the savings will be there when they need it. But under some states’ laws, an account that shows no activity can be declared abandoned and taken into state custody through a process called escheatment.

Pan walked through what seizure means in practice. When a state escheats an investment account, it typically liquidates the holdings — so even an investor who eventually recovers the money gets back only what the account was worth at seizure, with no credit for years of market gains. For retirement accounts, the forced liquidation can also trigger unforeseen tax consequences. And recovering the money at all can take years of paperwork and persistence. Meanwhile, some states are moving in the wrong direction, loosening their rules to make it easier to capture assets. 

“This is where the leadership of Congressmen Lawler and Liccardo is so important,” Pan said. “They’ve introduced the SAFER Act, a federal solution to a problem that exists across the United States. This patchwork of different legal standards, and the fact that the legal standards change constantly, creates a lot of confusion and creates this risk and harm that we’re so worried about.” 

In a panel discussion, the two lawmakers described the issue as an obvious place for Democrats and Republicans to find common ground, given Americans’ widespread use of investment accounts for saving.

“We are, for the most part, a group of Americans who sit on our investments, which is more or less the right strategy,” Liccardo said, noting that this is exactly the approach that inactivity standards put at risk. 

Liccardo pointed to the widely reported case of Walter Schramm, an investor who bought Amazon shares in the late 1990s and then did what many long-term investors do: leave the account be. Delaware deemed the account abandoned and liquidated the shares in 2008, when they worth about $8,000. By the time Schramm discovered what happened years later, the position would have been worth roughly $100,000.

The financial incentives driving state behavior are a concern, Liccardo noted. Unclaimed property has become one of Delaware’s largest sources of revenue, bringing in more than half a billion dollars a year — a powerful reason for states to loosen their standards rather than tighten them. 

Lawler contrasted legitimate unclaimed property programs and what some states are doing now. “It’s one thing to get an asset because it’s truly abandoned,” he said. “It’s another to basically target a group of investors who have a long-term strategy of just not touching the asset and being passive.”

The right standard, Lawler argued, is the obvious one: before seizing investment assets, a state should have to prove the owner is actually deceased. He posited that most Americans would be shocked to learn how little protection they have. “You think you have ownership of this asset, but the state, under current law, can just take it.”

The SAFER Act would establish federal guardrails ensuring that inactivity alone cannot be the basis for escheatment and that states confirm the death of an owner and that no estate or beneficiary has claimed the assets before escheating investment accounts. It would also require states to leave unclaimed investments in place, rather than liquidating them, until they can prove abandonment.

Both lawmakers said the path to fixing the problem is through public awareness of the threat some state laws pose to Americans financial security. “Ultimately the American people will rise up,” Liccardo said. “It may take a little while. We just have to get the information to them.”

Contact: media@ici.org 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ici-welcomes-bipartisan-sponsors-of-bill-to-stop-states-from-seizing-long-term-investors-savings-302832606.html

SOURCE Investment Company Institute

Continue Reading

Trending